top of page

Australian peanut therapy developer Aravax reveals positive Phase I trial results at AAAAI

February 25, 2019, Melbourne, Australia – Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical trials

Aravax, a clinical stage biotechnology company focused on developing the next generation of peanut allergy immunotherapy with advantages in safety and practicality, has presented its clinical trial results at one of the world’s most prominent allergy conferences today.

Melbourne-based Aravax today announced positive results from the Phase I trial of its peanut allergy therapy, at the 2019 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco. The trial data showed that Aravax’s therapy has a highly favorable safety profile, even in patients with severe peanut allergies.

bottom of page